Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4201680 | 0.92 | EPHX2 (0.49) | EPHX2APPBCHEACHERXFP1 | |
| SCHEMBL4217522 | 0.85 | EPHX2 (0.51) | EPHX2APPBCHEACHERXFP1 | |
| SCHEMBL4217529 | 0.85 | EPHX2 (0.51) | EPHX2APPBCHEACHERXFP1 | |
| SCHEMBL5528648 | 0.81 | WHR1 (0.50) | EPHX2APPBCHEACHE | |
| SCHEMBL5530309 | 0.79 | APP (0.41) | EPHX2APPBCHEACHECTNNB1 | |
| SCHEMBL4028504 | 0.79 | MCHR1 (0.59) | EPHX2APPBCHEACHE | |
| SCHEMBL4028510 | 0.79 | MCHR1 (0.59) | EPHX2APPBCHEACHE | |
| SCHEMBL4033615 | 0.77 | NPY5R (0.47) | APPBCHEACHEUSP2ALDH1A1 | |
| SCHEMBL4033618 | 0.77 | NPY5R (0.47) | APPBCHEACHEUSP2ALDH1A1 | |
| SCHEMBL5520050 | 0.76 | EPHX2 (0.61) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | EPHX2 3017/4885APP 1090/4885BCHE 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.